drugset
drugset / Trial / NCT00053950

Pyrazoloacridine and Stem Cell or Bone Marrow Transplantation in Treating Young Patients With High-Risk Neuroblastoma

NCT00053950 ↗

Phase 1 Terminated 42 enrolled National Cancer Institute (NCI)
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of pyrazoloacridine given together with peripheral stem cell or bone marrow transplantation in treating young patients with high-risk neuroblastoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

Timeline

Start
2002-12
Primary completion
2007-03
Completion
—

Outcome

Outcome not reported

Stopped: “Administratively complete.”

Drugs

EvaluationDrugModalityDoseRoute
Subject pyrazoloacridine Small molecule — Intravenous
Background filgrastim Protein / enzyme biologic — Intravenous

Indications

neuroblastoma